Medical Oncology

Columbia

Questions discussed in this category

How would you manage a premenopausal woman with a poorly differentiated pT2 HR+/HER2- breast cancer and 3/3 SLNs with ITCs?

Would you consider ALND and /or XRT to axilla?

1 Answer available

In the setting of COVID-19, would you perform a SLNB for a patient incidentally found to have microinvasive ER+ ILC in contralateral prophylactic mastectomy following neoadjuvant chemotherapy for a locally advanced triple positive breast cancer?

2 Answers available

How would you manage DCIS diagnosed in the first trimester of pregnancy?

1 Answer available

Is post-mastectomy chest wall radiotherapy indicated for DCIS with very close (<1mm) or positive margins?

4 Answers available

How do you counsel an early stage breast cancer patient with lupus regarding decisions on radiation?

3 Answers available

How do you manage a locally advanced hormone receptor positive invasive ductal carcinoma with neuroendocrine (small cell) features?

If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?

1 Answer available

In which patients will you consider the use of adjuvant pertuzumab for HER2 positive early stage breast cancer?

How does the modest results of the APHINITY trial impact your practice?

1 Answer available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2013-03-15

Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ.

International journal of radiation oncology, biology, physics, 2011-05-01

Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins?

International journal of radiation oncology, biology, physics, 2011-11-01

Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.

Lancet Oncol., 2014-11-01

Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.

Related Topics in Medical Oncology